196597-79-2

Usage

Uses

Used in Pharmaceutical Industry:
Acetonitrile, (1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-ylidene)-, (2E)is used as a chemical intermediate for the synthesis of pharmaceutical compounds. Its unique structure and reactivity make it a valuable component in the development of new drugs and medicinal agents.
Used in Agricultural Industry:
In the agricultural sector, Acetonitrile, (1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-ylidene)-, (2E)- serves as a building block for the synthesis of agrochemicals and pesticides. Its ability to participate in various chemical reactions allows for the creation of effective and targeted pest control solutions.
Used in Organic Electronics:
Acetonitrile, (1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-ylidene)-, (2E)may have potential applications in the field of organic electronics. Its electronic properties and compatibility with other organic materials could contribute to the development of novel electronic devices and components.
Used in Materials Science:
Acetonitrile, (1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-ylidene)-, (2E)-'s unique structure and properties also make it a candidate for use in materials science. Further research and studies may reveal additional uses and properties, such as its potential in the development of new materials with specific characteristics for various applications.
As the compound's applications and properties are still being explored, it is essential to conduct further research to fully understand its potential and optimize its use across different industries.

Upstream product

• 2537-48-6 diethyl 1-cyanomethylphosphonate 
• 196597-78-1 1,2,6,7-tetrahydro-8H-indeno[5,4-b]-furan-8-one 
• 496-16-2 2.3-dihydrobenzofuran 
• 55745-70-5 2,3-dihydro-benzofuran-5-carbaldehyde 
• 196597-65-6 ethyl (E)-3-(2,3-dihydrobenzofuran-5-yl)-2-propenoate 
• 196597-66-7 ethyl 3-(2,3-dihydro-1-benzofuran-5-yl)propanoate 
• 196597-67-8 ethyl 3-(7-bromo-2,3-dihydro-1-benzofuran-5-yl)propanoate 
• 227179-21-7 3-(6,7-dibromo-2,3-dihydro-benzofuran-5-yl)-propionyl chloride 
• 196597-77-0 4,5-dibromo-1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-one 
• 196597-76-9 ethyl 3-(6,7-dibromo-2,3-dihydrobenzofuran-5-yl) propionic acid 
• 196597-75-8 ethyl 3-(6,7-dibromo-2,3-dihydro-1-benzofuran-5-yl)propanoate 

Downstream Products

• 196597-16-7 N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]acetylamide 
• 196597-27-0 N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide 
• 1185516-79-3 (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)acetonitrile 
• 1221160-66-2 2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)acetonitrile 
• 196597-16-7 ramelteon 
• 196597-26-9 ramelteon 
• 448964-37-2 2?(1,6,7,8?tetrahydro?2H?indeno[5,4?b]furan?8?yl)?1?ethylamine 

Relevant academic research and scientific papers

Preparation method of ramelteon

The invention belongs to the field of medicinal chemistry, and mainly relates to a (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)-1-ethylamine compound represented by a formula I. The method has the advantages that the operation is simple, the steps are reduced compared with the previous method, the route is shortened, and the used solvent is single in variety, convenient to recycle and high in yield, wherein the formula I is defined in the specification.

Pharmaceutical preparation containing copolyvidone

A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated.

PROCESS FOR THE PREPARATION OF AN INTERMEDIATE FOR RAMELTEON

The present invention relates to a process for the preparation of (2E)- 1,2,6,7- tetrahydro-8H-indeno[5,4-b]furan-8-ylideneethanenitrile of Formula (I). The present invention further relates to a process for the preparation of ramelteon using (2E)-1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-ylideneethanenitrile of Formula (I) as an intermediate.

PROCESS FOR PREPARATION OF (S)-N-[2-(1,6,7,8-TETRAHYDRO-2H-INDENO[5,4-B]FURAN-8-YL)ETHYL] PROPIONAMIDE AND NOVEL INTERMEDIATES THEREOF

Disclosed herein process for preparation of (S)-Ramelteon and intermediates thereof.

SYNTHESIS OF (S)-N-[2-(1,6,7,8-TETRAHYDRO-2H-INDENO-[5,4-B]FURAN-8-YL)ETHYL]PROPIONAMIDE

The present invention relates in general to the field of organic chemistry and in particular to the preparation of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide, i.e. ramelteon, and analogues thereof.

PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES

An industrial process for production of high-purity optically active amine derivatives in high yield while inhibiting the formation of by-products, which comprises subjecting (E)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-ylidene)ethylamine to asymmetric reduction, catalytically reducing the obtained product at a reaction temperature of 40 to 100°C and a pH of 3 to 9, subjecting the obtained (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethylamine to propionylation, and then crystallizing the reaction mixture.

Approach to the stereoselective synthesis of melatonin receptor agonist Ramelteon via asymmetric hydrogenation

Asymmetric synthesis of a novel non-benzodiazepine hypnotic drug Ramelteon (TAK-375) was accomplished via asymmetric hydrogenation. Development of the substrate design revealed that a novel class of substrate, allylic acylamine 4a, was hydrogenated with a Ru-BINAP catalyst in 95% ee and 98% yield. The effectiveness and robustness of the reaction were demonstrated on a 700-g scale.

Pharmaceutical preparation containing copolyvidone

A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated.

PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE

A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated.

Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists

To develop a new therapeutic agent for sleep disorders, we synthesized a novel series of tricyclic indan derivatives and evaluated them for their binding affinity to melatonin receptors. In our previous paper, we proposed a conformation of the methoxy group favorable for the binding of the MT1 receptor. To fix the methoxy group in an active conformation, we decided to synthesize conformationally restricted tricyclic indan analogues with the oxygen atom in the 6-position incorporated into a furan, 1,3-dioxane, oxazole, pyran, morpholine, or 1,4-dioxane ring system. Among these compounds, indeno[5,4-b]furan analogues were found to be the most potent and selective MT1 receptor ligands and to have superior metabolic stability. The optimization of substituents led to (S)-(-)-22b, which showed very strong affinity for human MT1 (Ki = 0.014 nM), but no significant affinity for hamster MT3 (Ki = 2600 nM) or other neurotransmitter receptors. The pharmacological effects of (S)-(-)-22b were studied in experimental animals, and it was found that a dose of 0.1 mg/kg, po promoted a sleep in freely moving cats, as demonstrated by a decrease in wakefulness and increases in slow wave sleep and rapid eye movement sleep, which lasted for 6 h after administration. Melatonin (1 mg/kg, po) also had a sleep-promoting effect, though it lasted only 2 h. A new chiral method for the synthesis of (S)-(-)-22b starting from 60, which was prepared from 59 employing asymmetric hydrogenation with the (S)-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl-Ru complex, was developed. (S)-(-)-22b (TAK-375) is currently under clinical trial for the treatment of insomnia and circadian rhythm disorders.